MC
BLTE

Maverick Capital’s Belite Bio BLTE Stock Holding History

Maverick Capital’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61M Buy
+396,311
New +$60.7M 0.54% 43

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Maverick Capital's BLTE Position: Q2 2026 in Review

Maverick Capital opened a new position in Belite Bio (BLTE) in Q2 2026: 396,311 shares worth $61M. The stake represents 0.54% of the portfolio and ranks #43 among its holdings.

81 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Maverick Capital held 396,311 shares of Belite Bio worth $61M as of Q2 2026.
  • Belite Bio was a new Maverick Capital position in Q2 2026.
  • Belite Bio made up 0.54% of Maverick Capital's portfolio in Q2 2026, its #43 holding.
  • 81 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Maverick Capital's 13F filing for Q2 2026, filed 14 Aug 2026.